108 related articles for article (PubMed ID: 27746381)
21. [Efficacy of combination therapy with pegylated-interferon alfa-2a plus ribavirin in autoantibody-positive chronic hepatitis C patients].
Li YX; Yang YJ; Yang M; Chen LY; Lu JJ; Ma YJ; Liu K; Lei XZ; Tang H
Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):345-7. PubMed ID: 24025134
[TBL] [Abstract][Full Text] [Related]
22. Evolution of hepatitis C virus-specific T cell responses and cytokine production in chronic hepatitis C patients treated with high doses of interferon-alpha.
Alvarado Esquivel C; Elewaut A; Philippé J; Elewaut AE; Desombere I; Maertens G; Leroux-Roels G
Rev Invest Clin; 2002; 54(1):41-50. PubMed ID: 11995406
[TBL] [Abstract][Full Text] [Related]
23. The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C.
Wasmuth HE; Stolte C; Geier A; Dietrich CG; Gartung C; Lorenzen J; Matern S; Lammert F
BMC Infect Dis; 2004 Feb; 4():4. PubMed ID: 15040810
[TBL] [Abstract][Full Text] [Related]
24. Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C.
Muratori P; Muratori L; Guidi M; Granito A; Susca M; Lenzi M; Bianchi FB
Clin Infect Dis; 2005 Feb; 40(4):501-7. PubMed ID: 15712070
[TBL] [Abstract][Full Text] [Related]
25. [Serum autoantibodies of patients with chronic hepatitis C and the significance thereof in infection of hepatitis C virus].
Wu CH; Xu XY; Tian GS; Yu YY
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(6):390-3. PubMed ID: 16677548
[TBL] [Abstract][Full Text] [Related]
26. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin.
Perrella A; Sbreglia C; Atripaldi L; Esposito C; D'Antonio A; Perrella O
Scand J Gastroenterol; 2010; 45(2):250-5. PubMed ID: 19968615
[TBL] [Abstract][Full Text] [Related]
27. Molecular cell biology and immunobiology of mammalian rod/ring structures.
Carcamo WC; Calise SJ; von Mühlen CA; Satoh M; Chan EK
Int Rev Cell Mol Biol; 2014; 308():35-74. PubMed ID: 24411169
[TBL] [Abstract][Full Text] [Related]
28. Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?
Gluhovschi C; Gadalean F; Kaycsa A; Curescu M; Sporea I; Gluhovschi G; Petrica L; Velciov S; Bozdog G; Bob F; Vernic C; Cioca D
Immunopharmacol Immunotoxicol; 2011 Dec; 33(4):744-50. PubMed ID: 21320001
[TBL] [Abstract][Full Text] [Related]
29. Effect of interferon alfa and ribavirin treatment on hepatitis C virus RNA in serum and peripheral blood mononuclear cells in children with chronic hepatitis C.
Majda-Stanisławska E; Bednarek M; Jóźwiak B; Sidorkiewicz M; Piekarska A; Kuydowicz J
Acta Gastroenterol Belg; 2006; 69(2):187-90. PubMed ID: 16929613
[TBL] [Abstract][Full Text] [Related]
30. [Detection and the production mechanism of antinuclear antibodies (ANA) and anti-liver/kidney microsomal tpe 1 antibodies (anti-LKM1) in patients with chronic hepatitis C].
Bai L; Lu HY; Feng ZR; Yu M; Li WG; Gong WB; Zhao NE; Xu XY
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Aug; 23(4):278-81. PubMed ID: 20108773
[TBL] [Abstract][Full Text] [Related]
31. Primary biliary cholangitis with contemporary presence of anti-mithocondrial and anti-rods and rings autoantibodies: literature first case.
Assandri R
Gastroenterol Hepatol Bed Bench; 2019; 12(1):76-82. PubMed ID: 30949324
[TBL] [Abstract][Full Text] [Related]
32. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C.
Paraná R; Schinoni MI; de Freitas LA; Codes L; Cruz M; Andrade Z; Trepo C
Liver Int; 2006 Nov; 26(9):1148-54. PubMed ID: 17032416
[TBL] [Abstract][Full Text] [Related]
33. Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist's view.
Pellicano R; Smedile A; Peyre S; Astegiano M; Saracco G; Bonardi R; Rizzetto M
Minerva Gastroenterol Dietol; 2005 Mar; 51(1):55-61. PubMed ID: 15756146
[TBL] [Abstract][Full Text] [Related]
34. Ribavirin inhibits DNA, RNA, and protein synthesis in PHA-stimulated human peripheral blood mononuclear cells: possible explanation for therapeutic efficacy in patients with chronic HCV infection.
Meier V; Bürger E; Mihm S; Saile B; Ramadori G
J Med Virol; 2003 Jan; 69(1):50-8. PubMed ID: 12436477
[TBL] [Abstract][Full Text] [Related]
35. Induction of cytoplasmic rods and rings structures by inhibition of the CTP and GTP synthetic pathway in mammalian cells.
Carcamo WC; Satoh M; Kasahara H; Terada N; Hamazaki T; Chan JY; Yao B; Tamayo S; Covini G; von Mühlen CA; Chan EK
PLoS One; 2011; 6(12):e29690. PubMed ID: 22220215
[TBL] [Abstract][Full Text] [Related]
36. Endogenous IFNγ in chronic HCV genotype 4 patients treated with PEG-IFNα and ribavirin.
Sadeq R; Mohtady H; Al Badawy N; Ibrahim S; Omar AR; Husseiny MI; El Zowalaty M
J Infect Dev Ctries; 2013 Nov; 7(11):859-67. PubMed ID: 24240045
[TBL] [Abstract][Full Text] [Related]
37. [Significance of non-organ-specific autoantibodies in HCV-related chronic hepatitis].
Guidi M; Muratori P; Granito A; Muratori L; Pappas G; Bianchi FB
Recenti Prog Med; 2005 Dec; 96(12):589-93. PubMed ID: 16496742
[TBL] [Abstract][Full Text] [Related]
38. HCV RNA in serum and peripheral blood mononuclear cells after successful interferon therapy.
Mohamad HI; El-Bab HK; Kamal AM
Hepatogastroenterology; 2011; 58(107-108):932-6. PubMed ID: 21830419
[TBL] [Abstract][Full Text] [Related]
39. Microinjection of specific anti-IMPDH2 antibodies induces disassembly of cytoplasmic rods/rings that are primarily stationary and stable structures.
Keppeke GD; Andrade LE; Grieshaber SS; Chan EK
Cell Biosci; 2015; 5(1):1. PubMed ID: 25601894
[TBL] [Abstract][Full Text] [Related]
40. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).
Halfon P; Pérusat S; Bourlière M; Bronowicki JP; Trimoulet P; Benhamou Y; Leroy V; Marcellin P; Foucher J; Penaranda G; Chêne G; Couzigou P;
J Med Virol; 2010 Dec; 82(12):2027-31. PubMed ID: 20981789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
